文献速递白血病

鞘内三联治疗与鞘内甲氨蝶呤对高危B淋巴细胞白血病无病生存的影响:儿童肿瘤协作组AALL1131研究

Impact of Intrathecal Triple Therapy Versus Intrathecal Methotrexate on Disease-Free Survival for High-Risk B-Lymphoblastic Leukemia: Children's Oncology Group Study AALL1131.
PubMed 文献 · J Clin Oncol · 2020-06-04

儿童肿瘤协作组AALL1131研究在高危B细胞急性淋巴细胞白血病(B-ALL)患儿中随机比较诱导后鞘内三联治疗(ITT,含甲氨蝶呤、氢化可的松和阿糖胞苷)与鞘内甲氨蝶呤(IT MTX)的CNS预防效果。因无效性边界被跨越,随机入组于2018年3月关闭,结论为ITT未能显示优于IT MTX。两组5年诱导后无病生存率(DFS)和总生存率无显著差异,孤立骨髓复发、孤立CNS复发及骨髓合并CNS复发的累积发生率及毒性均无差异,神经认知结局亦无显著差异。

要点

  • ITT未能显示优于IT MTX,5年诱导后DFS为93.2%±2.1% vs 90.6%±2.3%(P=.85)。
  • 5年总生存率为96.3%±1.5% vs 96.7%±1.4%(P=.77),两组无显著差异。
  • 对于无 overt CNS 受累的B-ALL患儿,CNS预防的标准治疗仍为IT MTX。

核心结论

  • 诱导后ITT未能改善高危B-ALL患儿的5年DFS,ITT未能显示优于IT MTX。
  • 对于无 overt CNS 受累的B-ALL患儿,CNS预防的标准治疗仍为IT MTX。

研究设计与样本

  • 儿童肿瘤协作组AALL1131研究高危组,随机分配诱导后接受IT MTX或ITT。
  • 纳入新诊断NCI高危B-ALL或诱导期间达到特定MRD阈值的NCI标危B-ALL患儿,CNS3状态者不纳入。
  • 诱导后鞘内治疗共给予21至26剂,治疗期间及停止治疗1年内进行神经认知评估。
  • 因无效性边界被跨越,随机入组于2018年3月关闭。

主要发现

  • 5年诱导后DFS:IT MTX组93.2%±2.1% vs ITT组90.6%±2.3%(P=.85)。
  • 5年总生存率:IT MTX组96.3%±1.5% vs ITT组96.7%±1.4%(P=.77)。
  • 两组孤立骨髓复发、孤立CNS复发及骨髓合并CNS复发的累积发生率无差异。
  • 两组观察到的毒性无差异。
  • 两组神经认知结局无显著差异。

临床怎么用

  • 对于无 overt CNS 受累的B-ALL患儿,CNS预防的标准治疗仍为IT MTX。

局限性

  • 随机入组因无效性边界被跨越而于2018年3月关闭,结论为ITT未能显示优于IT MTX。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The high-risk stratum of Children's Oncology Group Study AALL1131 was designed to test the hypothesis that postinduction CNS prophylaxis with intrathecal triple therapy (ITT) including methotrexate, hydrocortisone, and cytarabine would improve the postinduction 5-year disease-free survival (DFS) compared with intrathecal methotrexate (IT MTX), when given on a modified augmented Berlin-Frankfurt-Münster backbone. PATIENTS AND METHODS: Children with newly diagnosed National Cancer Institute (NCI) high-risk B-cell acute lymphoblastic leukemia (HR B-ALL) or NCI standard-risk B-ALL with defined minimal residual disease thresholds during induction were randomly assigned to receive postinduction IT MTX or ITT. Patients with CNS3-status disease were not eligible. Postinduction IT therapy was given for a total of 21 to 26 doses. Neurocognitive assessments were performed during therapy and during 1 year off therapy. RESULTS: Random assignment was closed to accrual in March 2018 after a futility boundary had been crossed, concluding that ITT could not be shown to be superior to IT MTX. The 5-year postinduction DFS and overall survival rates (± SE) of children randomly assigned to IT MTX versus ITT were 93.2% ± 2.1% v 90.6% ± 2.3% (P = .85), and 96.3% ± 1.5% v 96.7% ± 1.4% (P = .77), respectively. There were no differences in the cumulative incidence of isolated bone marrow relapse, isolated CNS relapse, or combined bone marrow and CNS relapse rates, or in toxicities observed for patients receiving IT MTX compared with ITT. There were no significant differences in neurocognitive outcomes for patients receiving IT MTX compared with ITT. CONCLUSION: Postinduction CNS prophylaxis with ITT did not improve 5-year DFS for children with HR B-ALL. The standard of care for CNS prophylaxis for children with B-ALL and no overt CNS involvement remains IT MTX.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Salzer WL, Burke MJ, Devidas M, et al. Impact of Intrathecal Triple Therapy Versus Intrathecal Methotrexate on Disease-Free Survival for High-Risk B-Lymphoblastic Leukemia: Children's Oncology Group Study AALL1131. J Clin Oncol. 2020. PMID: 32496902. doi:10.1200/JCO.19.02892

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。